These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22283728)

  • 1. Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.
    Mason RP; Jacob RF; Kubant R; Jacoby A; Louka F; Corbalan JJ; Malinski T
    Br J Clin Pharmacol; 2012 Jul; 74(1):141-6. PubMed ID: 22283728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT1 receptor blocker potentiates shear-stress induced nitric oxide production via modulation of eNOS phosphorylation of residues Thr(495) and Ser(1177.).
    Barauna VG; Mantuan PR; Magalhães FC; Campos LC; Krieger JE
    Biochem Biophys Res Commun; 2013 Nov; 441(4):713-9. PubMed ID: 24211212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
    Harada N; Shimozawa N; Okajima K
    Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells.
    Myojo M; Nagata D; Fujita D; Kiyosue A; Takahashi M; Satonaka H; Morishita Y; Akimoto T; Nagai R; Komuro I; Hirata Y
    PLoS One; 2014; 9(5):e96948. PubMed ID: 24827148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.
    Watanabe T; Suzuki J; Yamawaki H; Sharma VK; Sheu SS; Berk BC
    Circulation; 2005 Sep; 112(12):1798-805. PubMed ID: 16172287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin II on nitric oxide generation in growing and resting rat aortic endothelial cells.
    Bayraktutan U
    J Hypertens; 2003 Nov; 21(11):2093-101. PubMed ID: 14597853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
    Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension.
    Savoia C; Arrabito E; Parente R; Nicoletti C; Madaro L; Battistoni A; Filippini A; Steckelings UM; Touyz RM; Volpe M
    Hypertension; 2020 Dec; 76(6):1753-1761. PubMed ID: 33070664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats.
    Xu L; Liu Y
    Physiol Res; 2013; 62(4):351-9. PubMed ID: 23590610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser
    Cho DH
    J Korean Med Sci; 2019 Nov; 34(42):e266. PubMed ID: 31674157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of I
    Luo Y; Zhang Q; Ding J; Yu M; Jiang J; Yang F; Wang S; Wang A; Wang L; Wu S; Xia Y; Lu D
    Biochem Biophys Res Commun; 2019 Aug; 516(3):613-618. PubMed ID: 31239152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
    Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
    J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
    Kalinowski L; Matys T; Chabielska E; Buczko W; Malinski T
    Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs.
    Presta I; Tassone EJ; Andreozzi F; Perticone M; Sciacqua A; Laino I; Musca D; Martino F; Sesti G; Perticone F
    Atherosclerosis; 2011 Dec; 219(2):463-7. PubMed ID: 21937042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling.
    Su KH; Tsai JY; Kou YR; Chiang AN; Hsiao SH; Wu YL; Hou HH; Pan CC; Shyue SK; Lee TS
    Cardiovasc Res; 2009 Jun; 82(3):468-75. PubMed ID: 19307231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.